Skip to main content
Equibles

UBS Group AG

Position in ABBV — AbbVie Inc.

CIK 1610520 ZURICH, V8
Back to ABBV Full portfolio

Position in ABBV

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$3,232,345,993
+$176,351,379 QoQ
Shares Held
12,845,120
-8.6% QoQ
Ownership
0.727%
of shares outstanding
% of Portfolio
0.67%
of 13F equity value
Holder Rank
#21
of 4,167 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 22% Shared 0% None 78%

Common Shares in ABBV Over Time

Shares Held

Position Value (USD)

Derivatives in ABBV

reported options exposure · as of Jun 30, 2026
CallValue
$347,253,386
CallShares
1,379,961
PutValue
$114,370,380
PutShares
454,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

UBS Group AG holds $17,056,271,930 across 20 Drug Manufacturers - General names. ABBV ranks #2 (19.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 3,865,931 $4,636,914,000
2 ABBV
AbbVie Inc.
This page 		12,845,120 $3,232,345,993
3 JNJ
Johnson & Johnson
 11,036,891 $2,803,039,201
4 MRK
Merck & Co., Inc.
 13,744,783 $1,766,204,613
5 AMGN
Amgen Inc
 3,308,695 $1,198,144,628
6 AZN
Astrazeneca PLC
 5,297,462 $1,004,504,738
7 GILD
Gilead Sciences, Inc.
 4,503,294 $568,946,162
8 BMY
Bristol Myers Squibb Co
 8,876,439 $511,460,413

All Filings in ABBV

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $114,370,380 454,500
2026-06-30 $3,232,345,993 12,845,120
2026-06-30 $347,253,386 1,379,961
2026-03-31 $79,971,073 367,700
2026-03-31 $3,055,994,614 14,051,196
2026-03-31 $155,113,868 713,200
2025-12-31 $126,652,007 554,300
2025-12-31 $2,405,295,946 10,526,920
2025-12-31 $225,519,630 987,000
2025-09-30 $175,669,398 758,700
2025-09-30 $133,575,426 576,900
2025-09-30 $2,713,240,358 11,718,236
2025-06-30 $86,034,870 463,500
2025-06-30 $2,191,148,315 11,804,484
2025-06-30 $115,678,384 623,200
2025-03-31 $2,454,074,231 11,712,840
2025-03-31 $202,102,992 964,600
2025-03-31 $189,615,600 905,000
2024-12-31 $131,035,980 737,400
2024-12-31 $194,332,720 1,093,600
2024-12-31 $2,235,502,956 12,580,208
2024-09-30 $2,269,856,046 11,494,106
2024-09-30 $246,928,992 1,250,400
2024-09-30 $160,116,784 810,800
2024-06-30 $183,217,664 1,068,200
2024-06-30 $103,546,624 603,700
2024-06-30 $2,037,231,709 11,877,517
2024-03-31 $1,913,544,854 10,508,209
2024-03-31 $270,837,330 1,487,300
2024-03-31 $129,163,530 709,300
2023-12-31 $270,259,621 1,743,948
2023-12-31 $170,484,356 1,100,112
2023-12-31 $1,689,966,751 10,905,122
2023-09-30 $205,553,740 1,379,000
2023-09-30 $124,375,664 834,400
2023-09-30 $1,574,071,357 10,559,985
2023-06-30 $132,237,495 981,500
2023-06-30 $1,496,994,321 11,111,069
2023-06-30 $93,933,756 697,200
2023-03-31 $165,633,241 1,039,300
2023-03-31 $99,877,179 626,700
2023-03-31 $1,736,692,972 10,897,239
2022-12-31 $232,847,688 1,440,800
2022-12-31 $108,068,607 668,700
2022-12-31 $1,746,811,293 10,808,807
2022-09-30 $42,329,834 315,400
2022-09-30 $166,916,977 1,243,700
2022-09-30 $1,324,519,557 9,869,008
2022-06-30 $54,188,008 353,800
2022-06-30 $1,493,666,857 9,752,330

Report a Problem

Category
Description
Email (optional, for follow-up)